AzTrials
AzTrials

ConstipationPhase 2NCT00299975

A Dose Determination Study of Chinese Herbal Medicine for Functional Constipation

A Phase 2 study testing MaZiRenWan (MZRW) Low dose, MaZiRenWan (MZRW) Median dose and MaZiRenWan (MZRW) High dose in people with Constipation, run by Hong Kong Baptist University at 1 site in China.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Functional constipation (FC) is common with 14.3% estimated prevalence in Hong Kong, but treatment for this condition in conventional medicine is suboptimal. Complementary and alternative medicines, especially Chinese herbal medicine (CHM) are used frequently by patients with FC, but there is little research evidence… Read more about this study

Who is it for?
Ages 18 to 65 years
Conditions the study is for
Constipation
What is being tested?
MaZiRenWan (MZRW) Low dose, MaZiRenWan (MZRW) Median dose and MaZiRenWan (MZRW) High dose
Type of treatment
Pill or oral medicine
Could I receive a placebo?
No, everyone receives an active treatment
How many people
97 participants
Where
1 siteChina
Study dates
Oct 2006to Oct 2007
Phase
Phase 2
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 65 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Clinical diagnosis of functional constipation with Rome II criteria
  • General stool type belongs to Type 1 to 4 according to Bristol Stool Form Scale
  • Complete spontaneous bowel movement≦2 movements per week

Who cannot join

  • Anti-diarrhoeal therapy
  • Drug-induced constipation
  • Medical history of important bowel pathology, such as inflammatory bowel disease, congenital or acquired megacolon / megarectum
  • Medical history of previous abdominal surgery
  • Taking chronic medications that contain any kind of herbs, mineral, or specific vitamin supplements
  • Medical history of carbohydrate malabsorption, hormonal disorder, cancer, diabetes mellitus, hypothyroidism, asthma, renal impairment and/or any other serious diseases
Show all 11Show fewer
  • History of laxative abuse
  • History of allergy to Chinese herbal medicine
  • Psychiatric or addictive disorders
  • Pregnancy or breast-feeding
  • Any other serious diseases

Trial locations and contacts

1 site in 1 country.

China1 site
  • Hong Kong Baptist University Chinese Medicine Clinic

    Hong Kong

Other trials in China

About this study

Official title: A Randomized Controlled Trial of Chinese Herbal Medicine in Three-dose Regimen for the Treatment of Functional Constipation

Functional constipation (FC) is common with 14.3% estimated prevalence in Hong Kong, but treatment for this condition in conventional medicine is suboptimal. Complementary and alternative medicines, especially Chinese herbal medicine (CHM) are used frequently by patients with FC, but there is little research evidence about these commonly used CHM. The purpose of the study is evaluate the efficacy and safety of CHM, as well as determining the optimal dosage.

Read the detailed description

Functional constipation (FC) is a common complaint in clinical practice, with the estimated prevalence 14.3% in Hong Kong, as nearly affecting 1 million Hong Kong People in different extent. It is comparable with western population, which is 15% in North America. By the definition of Rome II criteria, FC comprises a group of functional disorders, which presents as persistent difficult, infrequent or seemingly incomplete defecation.

Constipation is often perceived to be benign, easily treated condition with short-term treatment being relatively straightforward. However, the fact is the management of FC is perplexed as some subjects complain of constipation more than decade. Moreover, chronic constipation can develop into more serious bowel complaints, such as faecal impaction, incontinence and bowel perforations. There is also accumulating evidence shown that constipated subjects have significantly higher anxiety and depression scores and lower quality of life. Therefore, the demand of effective agents to normalize bowel function is extremely large.

Conventional treatment for constipation mainly relies on dietary fibre and laxatives. Although there is no credible evidence that any serious problem is associated with their prolonged use, the treatment of it has been suboptimal. First, a recent systematic review pointed out that there were paucity of trials for many commonly used agents, therefore, their use might not be well validated. Second, many patients with severe constipation do not respond adequately or lose of effectiveness after a short period of time. Third, many patients who intake dietary fibre complain of flatulence, distension, bloating and poor taste. As a result, the compliance is low as about 50%. Fourth, the use of osmotic laxatives, such as polyethylene glycol, become increasingly popular due to fewer side effects and better taste, however, the prices are much more expensive than other medications. Many constipation sufferers seek help from alternative medicine, especially from Chinese herbal medicine. For example, according to a telephone survey in Hong Kong, more than 85% of constipated subjects seek for coping strategies, such as asking for medical consultations, taking prescribed medicine and seeking for alternative therapy, involving Chinese medicine.

Traditional Chinese medicine (TCM) is particularly attractive as their effectiveness in treating functional disorders and retaining balance of body functions. The CHM used in study is derived from classic text of Chinese medicine (Shang Han Lun, Discussion of Cold-induced Disorders), which can "moisten the intestines, drain heat, promote the movement of qi and unblock the bowel".

It is well known that randomized controlled trial (RCT) is the gold standard to test the efficacy of intervention, thus in this project, we attempt to follow the basic requirements of RCT to testify the efficacy and safety of CHM on FC, as well as to determine the optimal dosage. We believe such study will benefit the advancement of CHM, or even as the foundation of research study in future.

Conditions
Constipation
Being tested
MaZiRenWan (MZRW) Low dose, MaZiRenWan (MZRW) Median dose, MaZiRenWan (MZRW) High dose
Keywords
Randomized Controlled Trials, Medicine, Chinese Traditional, Medicine, Herbal, Constipation
Medical subject headings
Constipation

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • MaZiRenWan (MZRW) Low doseDrug

    Also called Hemp Seed Pill

    Dissolved MaZiRenWan (MZRW) granule (2.5g/sachet) in 150 ml hot water, take orally twice daily for 8 weeks

  • MaZiRenWan (MZRW) Median doseDrug

    Also called Hemp Seed Pill

    Dissolved MaZiRenWan (MZRW) granule (5.0g/sachet) in 150 ml hot water, take orally twice daily for 8 weeks

  • MaZiRenWan (MZRW) High doseDrug

    Also called Hemp Seed Pill

    Dissolved MaZiRenWan (MZRW) granule (7.5g/sachet) in 150 ml hot water, take orally twice daily for 8 weeks

Study groups in NCT00299975
Study groupRoleWhat they receive
MaZiRenWan (MZRW) Low doseExperimentalMaZiRenWan (MZRW) Low dose 2.5g sachet by mouth, twice daily for 8 weeks
Receives: Drug: MaZiRenWan (MZRW) Low dose
MaZiRenWan (MZRW) Median doseExperimentalMaZiRenWan (MZRW) Median dose 5.0g sachet by mouth, twice daily for 8 weeks
Receives: Drug: MaZiRenWan (MZRW) Median dose
MaZiRenWan (MZRW) High doseExperimentalMaZiRenWan (MZRW) High dose 7.5g sachet by mouth, twice daily for 8 weeks
Receives: Drug: MaZiRenWan (MZRW) High dose

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Responder for Complete Spontaneous Bowel Movement (CSBM)

    Participants with a mean increase of CSBM>=1 movement per week compared with the last 14 days of the run-in period were defined as responders.CSBM referred to the feeling that defecation led to complete passage of stool rather than partial or incomplete evacuation without the use of any laxative or enema within 24 hours.

    Measured: Week3-10

Secondary outcomes (15)
  1. Responder for Complete Spontaneous Bowel Movement (CSBM)

    Participants with a mean increase of CSBM>=1 movement per week compared with the last 14 days of the run-in period were defined as responders. CSBM referred to the feeling that defecation led to complete passage of stool rather than partial or incomplete evacuation without the use of any laxative or enema within 24 hours.

    Measured: Week11-18

  2. Bowel Movement

    Measured: Baseline(Week1-2), Within treatment(Week3-10) & Within follow-up(Week11-18)

  3. Complete Spontaneous Bowel Movement (CSBM)

    CSBM referred to the feeling that defecation led to complete passage of stool rather than partial or incomplete evacuation without the use of any laxative or enema within 24 hours.

    Measured: Baseline(Week1-2), Within treatment(Week3-10) & Within follow-up(Week11-18)

  4. Global Symptoms Improvement

    Participants were asked to rate their impression of change in constipation by comparing with their baseline (Wk2) at the visits during the treatment (Wk6), end of treatment (Wk10) and end of follow-up (Wk18) with scores from 0 to 6 represented markedly worse or better respectively. The response categories were collapsed to simply "improved" for score 4 to 6, "same" for score 3 or "worse" for score 0 to 2.

    Measured: Week6, 10 & 18

  5. Severity of Constipation

    It was a 7-point ordinal scale from 0=not at all to 6=very severe.

    Measured: Baseline(Week2), Within treatment(Week6), End of treatment(Week10) & End of follow-up(Week18)

  6. Sensation of Straining

    It was a 7-point ordinal scale from 0=not at all to 6=very severe.

    Measured: Baseline(Week2), Within treatment(Week6), End of treatment(Week10) & End of follow-up(Week18)

  7. Incomplete of Evacuation

    It was a 7-point ordinal scale from 0=not at all to 6=very severe.

    Measured: Baseline(Week2), Within treatment(Week6), End of treatment(Week10) & End of follow-up(Week18)

  8. Sensation of Bloating

    It was a 7-point ordinal scale from 0=not at all to 6=very severe.

    Measured: Baseline(Week2), Within treatment(Week6), End of treatment(Week10) & End of follow-up(Week18)

  9. Sensation of Abdominal Pain/Cramping

    It was a 7-point ordinal scale from 0=not at all to 6=very severe.

    Measured: Baseline(Week2), Within treatment(Week6), End of treatment(Week10) & End of follow-up(Week18)

  10. Passing of Gas

    It was a 7-point ordinal scale from 0=not at all to 6=very severe.

    Measured: Baseline(Week2), Within treatment(Week6), End of treatment(Week10) & End of follow-up(Week18)

  11. Adverse Effects (e.g. Renal and Liver Function Tests)

    Measured: pre-treatment & post-treatment

  12. Blood Urea Level

    Measured: Pre-treatment(Week2) & Post-treatment(Week10)

  13. Blood Creatinine Level

    Measured: Pre-treatment(Week2) & Post-treatment(Week10)

  14. Serum Glutamic Pyruvic Transaminase(SGPT) Level

    Measured: Pre-treatment(Week2) & Post-treatment(Week10)

  15. Serum Glutamic Oxaloacetic Transaminase(SGOT) Level

    Measured: Pre-treatment(Week2) & Post-treatment(Week10)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted7 Mar 2006 (estimated)
  2. Study startOct 2006
  3. Primary completionAug 2007
  4. Study completionOct 2007

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Participant
Enrolment
97 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00299975
Sponsor's protocol ID
PID-001
Status last verified
Apr 2015
First submitted
6 Mar 2006
Last updated
24 Apr 2015
Data monitoring committee
Yes

Publications

  • Cheng CW, Bian ZX, Zhu LX, Wu JC, Sung JJ. Efficacy of a Chinese herbal proprietary medicine (Hemp Seed Pill) for functional constipation. Am J Gastroenterol. 2011 Jan;106(1):120-9. doi: 10.1038/ajg.2010.305. Epub 2010 Nov 2.

    PubMed 21045817

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing MaZiRenWan (MZRW) Low dose, MaZiRenWan (MZRW) Median dose and MaZiRenWan (MZRW) High dose in people with Constipation, run by Hong Kong Baptist University at 1 site in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 24 Apr 2015. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 16 Dec 2011). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Responder for Complete Spontaneous Bowel Movement (CSBM) (time frame: Week3-10). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT00299975, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Apr 2015.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in